The much-anticipated Anthem Biosciences IPO opened for subscription on 14 July 2025 and will remain available to investors until 16 July 2025. As a Contract Research, Development, and Manufacturing Organization (CRDMO), Anthem Biosciences is drawing keen interest from institutional and retail investors alike. Backed by a strong growth trajectory and a healthy financial performance, this IPO is expected to make a significant impact in the Indian pharmaceutical and biotech sectors.
Here’s a detailed 1000-word SEO-optimized overview of the Anthem Biosciences IPO, including its GMP, subscription status, price details, expert reviews, and whether you should subscribe.
📌 Overview of Anthem Biosciences IPO
Anthem Biosciences Limited is a fully integrated CRDMO that offers drug discovery, development, and manufacturing services across New Chemical Entities (NCEs) and New Biological Entities (NBEs). The company operates across the pharma value chain, offering end-to-end solutions for global pharmaceutical firms.
The company has opened its initial public offering (IPO) on 14 July 2025 and aims to raise ₹3,395 crore via a 100% Offer-for-Sale (OFS).
💰 Anthem Biosciences IPO Price Band and Lot Size
- IPO Price Band: ₹540 to ₹570 per equity share
- Face Value: ₹2 per share
- Lot Size: 26 shares per lot
- Minimum Investment (Retail): ₹14,820 (based on upper price band)
- Issue Size: ₹3,395 crore (entirely OFS)
- IPO Type: Book-built issue
- Listing Exchanges: BSE and NSE
- IPO Registrar: KFin Technologies Ltd
🧮 Subscription Status (Day 1)
As of 4:15 PM on Day 1 (14 July 2025):
- Overall Subscription: 0.64 times
- Retail Investors: 0.53 times
- Non-Institutional Investors (NII): 1.24 times
- Qualified Institutional Buyers (QIB): 0.36 times
The strong NII response shows high interest from high-net-worth individuals and seasoned investors, indicating trust in the company’s business model.
📈 Anthem Biosciences IPO GMP Today
According to market observers, the Grey Market Premium (GMP) for Anthem Biosciences IPO is ₹101 on 14 July 2025. This suggests a potential listing price of ₹671 (₹570 + ₹101), implying a 17.7% listing gain from the upper band.
A rising GMP indicates positive investor sentiment in the unlisted market, which can often be a leading indicator of a good listing performance.
📅 Important Dates
| Event | Date |
| IPO Open Date | 14 July 2025 |
| IPO Close Date | 16 July 2025 |
| Allotment Date | 17 July 2025 |
| Refund Initiation | 18 July 2025 |
| Shares in Demat | 19 July 2025 |
| Listing Date | 21 July 2025 |
🧾 Financial Highlights of Anthem Biosciences
- FY25 Revenue: ₹1,844.55 crore
- Profit After Tax (PAT): ₹451 crore
- Net Profit Margin: 23.4%
- Earnings Per Share (EPS): ₹8.04
- Price-to-Earnings (P/E) Ratio: 67.16–70.90 (fully diluted basis)
- Post-Issue Market Cap: ₹31,867.3 crore
These numbers reflect the company’s robust profitability and efficient business model. The high net margins and solid EPS make it an attractive pick in the pharmaceutical and biotech sector.
💼 Lead Managers
The IPO is being led by some of the most respected investment banks and advisory firms:
- JM Financial
- Citigroup Global Markets
- JP Morgan India
- Nomura Financial Advisory
Their involvement adds credibility and trust to the IPO process.
🔍 Expert Reviews: Buy or Not?
👉 Arun Kejriwal (Founder, Kejriwal Research and Investment Services):
“The company is a top-tier CRDMO with integrated services from drug discovery to manufacturing. The promoter’s decision to not sell a single share is a strong confidence signal. I recommend subscribing to the IPO.”
👉 Anand Rathi Advisors:
“The company has outperformed its peers in terms of profitability and aims to grow further by venturing into speciality chemicals, peptides, probiotics, and more. The valuation appears fair and presents a good long-term opportunity.”
💡 Key Strengths of Anthem Biosciences
- ✅ End-to-End Drug Development: Integrated model gives it a competitive advantage over pure-play CDMOs.
- ✅ Consistent Profitability: High net margins and a growing top line.
- ✅ Global Clientele: Works with leading pharmaceutical companies globally.
- ✅ Strong Promoter Confidence: Promoter retaining 52% post-IPO shows long-term commitment.
- ✅ Technological Edge: Investment in R&D and complex molecules is a strategic growth lever.
⚠️ Risks to Consider
- ❌ 100% OFS Issue: No fresh capital is being infused into the business.
- ❌ High Valuation: PE ratio above 67 may be considered steep by some value investors.
- ❌ Dependence on Foreign Markets: A large chunk of revenue comes from international clients, which exposes the company to forex and regulatory risks.
🤔 Should You Invest?
If you are a medium to long-term investor looking for exposure in the high-growth pharma services and biotechnology space, Anthem Biosciences IPO could be a compelling pick. The company’s fundamentals are strong, and expert reviews are positive.
While the valuation is on the higher side, the GMP, promoter commitment, and industry position justify it. However, short-term investors should also be mindful of market volatility around the listing.
✅ Final Verdict: Subscribe for Long-Term Gains
The Anthem Biosciences IPO offers a strong combination of growth, profitability, and promoter confidence. With solid backing from institutional investors, favorable grey market trends, and robust business fundamentals, this IPO is well-positioned to deliver value.